COMMUNIQUÉS West-GlobeNewswire

RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call
29/10/2026
LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Helsinn announces UK MHRA approval of AKYNZEO® Oral Suspension
29/10/2026
Lugano, Switzerland – October 29 th , 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that the UK Medicines and [...]
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
29/10/2026
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond ZUG, Switzerland, October 29 th , 2026 -- Oculis [...]
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
29/10/2026
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond ZUG, Switzerland, October 29 th , 2026 -- Oculis [...]
Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform
29/10/2026
October 29, 2026 New CE-marked solution leverages the industry-leading Philips Azurion platform to integrate CT-derived insights and treatment planning directly into the procedural workflow, helping physicians make [...]
Exogenus Therapeutics leads a €13 million EU-funded consortium to advance a new secretome-based therapy for osteoarthritis
29/10/2026
ExoCordOA, a f ive-year project, led by Exogenus Therapeutics and backed by Horizon Europe, brings together ten organisations spanning biotechnology, clinical development, regulation, GMP manufacturing, imaging, [...]
ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline
29/10/2026
Financing led by Asabys, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF) Proceeds will accelerate the expansion of ALLOX’s high-throughput biophysics and AI drug discovery [...]
Coloplast opens new factory in Portugal to support global growth
29/10/2026
Coloplast today inaugurates its largest manufacturing site to date, a two-floor 50,000 m2 facility in Felgueiras, Portugal, expanding the company’s production capacity to meet growing global demand for continence care [...]
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd.
29/10/2026
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd. TME Pharma receives €150,000 for 6 months of exclusivity to negotiate a definitive agreement for worldwide rights to NOX-A12 TMS Co., [...]
TME Pharma signe un accord de négociation exclusif et contraignant avec la société japonaise TMS Co., Ltd.
29/10/2026
TME Pharma signe un accord de négociation exclusif et contraignant avec la société japonaise TMS Co., Ltd. TME Pharma TME Pharma reçoit 150 000 € en échange de 6 mois d’exclusivité pour négocier un accord définitif [...]
Vistin Pharma ASA (VISTN): Key information relating to the cash dividend
29/10/2026
The Board of Directors has resolved to pay an additional ordinary cash dividend of NOK 0.50 per share in November, pursuant to the authorization granted by the Annual General Meeting on 20 May 2026. Dividend amount (per [...]
Vistin Pharma ASA: Third quarter and YTD 2026 financial results
29/10/2026
Vistin Pharma ASA: Third quarter and YTD 2026 financial results Oslo, Norway, 29 October 2026 Vistin Pharma ASA (VISTN) today announces its financial results for the third quarter and year to date 2026. Revenue in the [...]
Cardiolyse Launches AI-Powered ECG Workspace for 12-Lead ECG Review from First Read to Clinician Sign-Off
29/10/2026
Cardiolyse Launches AI-Powered ECG Workspace for 12-Lead ECG Review from First Read to Clinician Sign-Off Rebuilt platform combines AI-powered 12-lead ECG analysis, editable findings, and clinician sign-off in one [...]
Cardiolyse lance ECG Workspace : l’analyse des ECG à 12 dérivations assistée par l’IA, de la première lecture à la validation médicale
29/10/2026
Cardiolyse lance ECG Workspace : l’analyse des ECG à 12 dérivations assistée par l’IA, de la première lecture à la validation médicale Plateforme repensée : analyse des ECG à 12 dérivations par l’IA, résultats [...]
ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES
29/10/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance
29/10/2026
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant) sales reached CHF 142 million in the first nine months of 2026, with growth accelerating quarter-on-quarter. Idorsia reaffirms its full-year 2026 [...]
Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists
29/10/2026
Ad hoc announcement pursuant to Art. 53 LR Dedicated launch capital and shared participation in future revenues create a focused and capital-efficient pathway to realize the potential of TRYVIO/JERAYGO. Idorsia to host [...]
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
29/10/2026
SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
29/10/2026
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum